MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors.
See the rest here:
Theratechnologies Appoints Two New Board Members
Related Post
- Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure - January 17th, 2021
- Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update - January 17th, 2021
- SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones - January 17th, 2021
- PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology - January 17th, 2021
- Grey Cloak Tech Fuel4Thought™ Migraine Formula Results Published in World Journal of Advanced Research and Reviews - January 17th, 2021
- One World Pharma Receives Colombian Approval for Five THC Strains - January 17th, 2021
- Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in... - January 17th, 2021
- RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing - January 17th, 2021
- Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference - January 17th, 2021
- Ceapro Inc. to Present at NobleCon17 - January 17th, 2021
- Tauriga Sciences Inc. Completes Payment for the Entirety of its Initial Production Run of its Caffeine Infused Version of Tauri-Gum - January 17th, 2021
- DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years - January 17th, 2021
- Dr. Han Myint Appointed as NextCure’s Chief Medical Officer - January 17th, 2021
- AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET - January 17th, 2021
- Global WholeHealth Partners, Corp (GWHP: OTC) Announces the Beginning Research for Saliva COVID 19 SARS 2 Antigen (N+S) Tests - January 17th, 2021
- Qilian International Holding Group Limited Announces Closing of Initial Public Offering - January 17th, 2021
- ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer - January 17th, 2021
- Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant... - January 17th, 2021
- TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference - January 16th, 2021
- Manager’s transactions - January 16th, 2021
- VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC - January 16th, 2021
- MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors - January 16th, 2021
- Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital - January 16th, 2021
- Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration - January 16th, 2021
- Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer - January 16th, 2021
- Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17... - January 16th, 2021
- BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS)... - January 16th, 2021
- Golden Leaf Holdings Announces Oversubscribed Private Placement and increase in offering size - January 16th, 2021
- Aeterna Zentaris to Present at NobleCon17 - January 16th, 2021
- Tauriga Sciences Inc. Taking Immediate Steps to Strengthen its Board of Directors and Corporate Governance Protocols With Aim Towards Future Up-List... - January 16th, 2021
- Biomerica Reports Fiscal 2021 Second Quarter Financial Results and Provides Business Update - January 16th, 2021
- Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares - January 16th, 2021
- Tower One Provides Construction and Business Update for the Month of December 2020 - January 16th, 2021
- Valneva Announces Amendment to Deerfield and OrbiMed Debt Facility Terms - January 16th, 2021
- Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux - January 16th, 2021
- Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th - January 16th, 2021
- Muama Ryoko Reviews - Best 4G Wifi Router? - Product Review by Mike Vaughn - January 16th, 2021
- Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast - January 16th, 2021
- Immune Therapeutics Inc. Spinoff Cytocom, Inc. to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During “J.P. Morgan Week... - January 12th, 2021
- Tiziana Life Sciences to Present at Biotech Showcase Digital 2021 - January 12th, 2021
- Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee - January 12th, 2021
- Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021 - January 12th, 2021
- 22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes - January 12th, 2021
- Myriad Genetics Forms Strategic Partnership with Illumina in Oncology - January 12th, 2021
- Alexis RIDEAU appointed CEO of DEINOVE - January 12th, 2021
- Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of... - January 12th, 2021
- Gilead holds 25.54% of Galapagos shares - January 12th, 2021
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - January 12th, 2021
- GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020 - January 12th, 2021
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 12th, 2021
- EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues - January 12th, 2021
- Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene - January 12th, 2021
- Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference - January 12th, 2021
- INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium - January 12th, 2021
- IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant - January 12th, 2021
- Generation Bio Announces Closing of Public Offering - January 12th, 2021
- T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus - January 12th, 2021
- Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units - January 12th, 2021
- Women In Bio Elects Katie Williams, Associate Director of Business Development at Applied BioMath, as 2021 President-Elect - January 8th, 2021
- ExCellThera announces UM171 mechanism of action - January 8th, 2021
- Valneva Reports FY 2020 Cash of Over €200 Million - January 8th, 2021
- Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility - January 8th, 2021
- Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference - January 8th, 2021
- Vincera Pharma Announces Name Change to Vincerx - January 8th, 2021
- BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science - January 8th, 2021
- AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference - January 8th, 2021
- Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors - January 8th, 2021
- Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell... - January 8th, 2021
- Shattuck Labs to Present at H.C. Wainwright BioConnect 2021 Conference - January 8th, 2021
- Eve & Co Issues Corporate Update - January 8th, 2021
- Neuronetics to Participate at the 23rd Annual ICR Westwicke Conference - January 8th, 2021
- XORTX Announces Private Placement - January 8th, 2021
- Adamas to Present at Upcoming ICR Conference - January 8th, 2021
- Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021” - January 8th, 2021
- argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline - January 8th, 2021
- Bone Therapeutics SA: Notice of Extraordinary Shareholders’ Meeting on 8 February 2021 - January 8th, 2021
- Cullinan Management Announces Pricing of Upsized Initial Public Offering (CORRECTION) - January 8th, 2021
- Novozymes completes acquisition of Microbiome Labs - January 8th, 2021
- Radius Health, Inc. Announces Acquisition of Orphan Disease Program - January 6th, 2021
- Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - January 6th, 2021
Recent Comments